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Abstract
Background: Early randomized controlled trials have suggested that neuraxial blockade may reduce cardiorespiratory
complications after non-cardiothoracic surgery, but recent larger trials have been inconclusive. We conducted a pilot study
to assess the feasibility of conducting a large multicentre randomized controlled trial in Canada.
Methodology/Principal Findings: After Research Ethics Board approvals from the participating institutions, subjects were
recruited if they were $45 years old, had an expected hospital stay $48 hours, were undergoing a noncardiothoracic
procedure amenable to epidural analgesia, met one of six risk criteria, and did not have contraindications to neuraxial
blockade. After informed consent, subjects were randomly allocated to combined epidural analgesia (epidural group) and
neuraxial anesthesia, with or without general anesthesia, or intravenous opioid analgesia (IV group) and general anesthesia.
The primary outcomes were the rate of recruitment and the percents of eligible patients recruited, crossed over, and
followed completely. Feasibility targets were defined a priori. A blinded, independent committee adjudicated the secondary
clinical outcomes. Subjects were followed daily while in hospital and then at 30 days after surgery. Analysis was intention-
to-treat. Over a 15-month period, the recruitment rate was 0.560.3 (mean6SEM) subjects per week per centre; 112/494
(22.7%) eligible subjects were recruited at four tertiary-care teaching hospitals in Canada. Thirteen (26.5%) of 49 subjects in
the epidural group crossed over to the IV group; seven (14.3%) were due to failed or inadequate analgesia or complications
from epidural analgesia. Five (9.8%) of 51 subjects in the IV group crossed over to the epidural group but none were due to
inadequate analgesia or complications. Ninety-eight (97.0%) of 101 subjects were successfully followed up until 30 days
after their surgery.
Conclusion/Significance: Of the criteria we defined for the feasibility of a full-scale trial, only the follow-up target was met.
The other feasibility outcomes did not meet our preset criteria for success. The results suggest that a large multicentre trial
may not be a feasible design to study the perioperative effects of neuraxial blockade.
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Introduction
Perioperative cardiorespiratory events are frequent complica-
tions of non-cardiothoracic surgery and result in significant
morbidity, mortality, and cost [1–3]. Mortality after noncardiac
surgery ranges from 0.3% to 3.6% depending on the level of risk
[4,5]. The incidence has remained unchanged over the past
decade [4]. In one national study of perioperative outcomes and
death, cardiac failure, respiratory complications, and cardiac
arrest were the most frequent postoperative complications [6].
Moderate-sized prospective cohort studies report that in patients
with or at risk of cardiac disease undergoing non-cardiac surgery,
2.4% to 5.8% will suffer a major cardiac event [2]. Rates of
postoperative pneumonia in non-cardiothoracic surgery vary from
9% to 40% [3], demonstrating both the heterogeneity in patients
undergoing non-cardiothoracic surgery and the magnitude of the
problem.
Results from randomized controlled trials (RCTs) and meta-
analyses have suggested a number of potentially beneficial drugs
(e.g., beta-blockers, calcium channel blockers, statins, alpha-2
agonists) to reduce perioperative cardiovascular events [7–11]
and potentially beneficial interventions (e.g., lung expansion
maneuvers, selective nasogastric decompression) to reduce peri-
operative pulmonary events [12]. However, with the exception of
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ISchemia Evaluation (POISE) Study [14], the evidence is based on
data from RCTs with sample sizes of less than 1000 subjects.
Considering the high frequency of cardiorespiratory complica-
tions following non-cardiothoracic surgery, an ideal intervention
would reduce both cardiac and respiratory complications in a wide
range of perioperative settings. Perioperative neuraxial blockade
may well meet this criterion. Neuraxial blockade has potentially
beneficial effects on the cardiovascular, hematological, and
respiratory systems [15]. The resultant changes in catecholamines,
prothrombotic mediators, and respiratory function begin during
surgery and continue postoperatively; thus, maximally effective
neuraxial blockade should be administered intraoperatively and
continued postoperatively. The benefits achieved by neuraxial
blockade should, in theory, reduce perioperative thrombotic (e.g.,
myocardial infarction, deep vein thrombosis) and respiratory (e.g.,
pneumonia, respiratory failure) events.
Several meta-analyses have evaluated the effect of neuraxial
blockade on perioperative outcomes [16–20]. Based primarily on
data from small studies, the meta-analyses found reductions in 30-
day all-cause postoperative mortality (odds ratio [OR] 0.70; 95%
confidence interval [CI] 0.54–0.90), deep vein thrombosis (OR
0.56; 95% CI 0.43–0.72), pulmonary embolism (OR 0.45; 95% CI
0.29–0.69), pneumonia (OR 0.61; 95% CI 0.48–0.76), and
respiratory depression (OR 0.41; 95% 0.23–0.73) and showed a
trend toward reduced postoperative myocardial infarction with the
use of neuraxial blockade (OR 0.67; 95% CI 0.45–1.00) [16].
There was no difference in all-cause mortality or myocardial
infarction between postoperative epidural analgesia and intrave-
nous analgesia of at least 24 hour duration (OR 0.74; 0.40–1.37)
[17]; however, there was a statistically significant reduction for
myocardial infarction in patients receiving thoracic epidural
analgesia (OR 0.64; 95% CI 0.42–0.97) [18]. Postoperative
epidural analgesia with local anesthetics also reduced respiratory
infections compared to systemic narcotics (relative risk 0.36; 95%
CI 0.21–0.65) [19]. In summary, meta-analyses show consistent
strong trends toward reduction in all-cause mortality with
neuraxial anesthesia and analgesia. Data are consistent with
decreases in cardiovascular and pulmonary events contributing to
reductions in all-cause mortality, with both intraoperative and
postoperative blockade playing a role in reducing mortality.
Subsequently, two moderate-size RCTs have examined the
effect of perioperative neuraxial blockade in moderate- to high-risk
patients undergoing major abdominal operations [21,22]. Both
RCTs compared combined epidural and general anesthesia and
postoperative epidural analgesia to general anesthesia and
postoperative intravenous (i.v.) opioid analgesia. In contrast to
the meta-analyses, the two studies observed trends toward
increased 30-day all-cause mortality in the epidural blockade
groups (epidural 23/447, i.v. 19/441; p=0.67) [21], (epidural 20/
514, i.v. 17/507; p=0.74) [22]. There were no differences in
major postoperative morbidity in the neuraxial group with the
exception of reduced respiratory failure overall (epidural 104/447,
i.v. 133/441; p=0.02) [21] and reduced nonfatal myocardial
infarction in a subgroup of patients undergoing abdominal aortic
surgery (epidural 5/184, i.v. 15/190; p=0.05) [22].
The trends toward reduction in cardiorespiratory events with
neuraxial blockade observed in meta-analyses and RCTs are
encouraging, but the discrepancy between meta-analyses and
moderate-size RCTs with regards to all-cause mortality raises
doubts about the use of neuraxial blockade. Because of the
susceptibility to publication bias, and previous instances in which
subsequent trials contradicted results of meta-analyses of small
trials, clinicians are legitimately skeptical about considering a
meta-analysis of many small trials as providing definitive evidence.
The numbers of subjects in clinical trials are still insufficient to
detect clinically relevant differences in most perioperative
complications [20]. A large RCT is needed to inform clinicians
of the benefits and harm of neuraxial blockade with regards to
perioperative cardiorespiratory events.
Prior to embarking on a large, multicentre trial we needed a
pilot study to inform us of several key issues. The objectives of the
PostOperative Epidural Trial (POET) Pilot Study were 1) to
determine the feasibility of recruiting and following patients in a
timely manner and 2) to estimate the incidence rate of the primary
clinical outcome to be used in size calculations for a large definitive
trial. Specifically, we wished to determine the recruitment rate
across centres, the percent of eligible patients recruited, the rates of
crossover from one analgesic modality to the other, and the
percent of successful follow-up.
Materials and Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Ethics statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. Four Canadian tertiary-care
teaching hospitals participated in this study, which was approved
by the Research Ethics Boards at all of the centres (Hamilton
Health Sciences, Ottawa Hospital, University Health Network,
University of British Columbia-Vancouver Coastal Health Au-
thority). All patients provided written informed consent.
Eligibility criteria
Patients were eligible to participate in this study if they were at
least 45 years of age, had an expected hospital length of stay of at
least 48 hours, were undergoing a non-cardiothoracic surgical
procedure that was amenable to neuraxial blockade, and met at
least one of six criteria predictive of moderate- to high-risk for
perioperative cardiorespiratory events (Tables 1 and 2). Patients
were excluded from participation if they had a contraindication to
neuraxial blockade, a prior adverse reaction to local anesthetics or
opioids, previous coronary artery bypass graft surgery with
complete revascularization in the preceding five years and no
subsequent evidence of cardiac ischemia, or a history of
pneumonia within two weeks of surgery. We also excluded
patients who were already intubated or mechanically ventilated or
had a concomitant life-threatening disease that was likely to limit
their lifespan to less than 30 days.
Patients were informed about the study during their visit to the
centres’ preoperative assessment clinics. Study coordinators kept a
logofalleligiblepatients,theeligiblepatientswhowerenotrecruited
and the reasons for their lack of participation, and the patients who
were successfully recruited into the study. Study coordinators
obtained informed consent from each subject; whenever possible,
subjects had at least 24 hours to consider their participation.
Randomization
After informed consent, subjects were randomly allocated to
receive neuraxial anesthesia with or without general anesthesia
and postoperative epidural analgesia (epidural group) or general
anesthesia and postoperative i.v. opioid analgesia (IV group). We
stratified the randomization by centre and by type of surgery
(lower limb surgery vs. non-lower limb surgery) on the basis that
epidural catheters would be sited in the lumbar and thoracic levels
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coordinating office, who was not involved with any of the
participating centres, generated the allocation sequence in random
permuted blocks by computer; the sequence was stored on a secure
SQL Server database in the coordinating office. At each centre, a
research assistant obtained the allocation for a subject by logging
onto a secure study website maintained by the central coordinating
office. Allocation took place one to two hours before surgery to
reduce the risk of including subjects who did not receive their
scheduled surgery. The allocation was printed and placed in an
opaque envelope, which was delivered to the anesthesiologist when
the subject entered the operating room.
Epidural group
In the epidural group, anesthesia was achieved by neuraxial
blockade (epidural or combined spinal-epidural) with or without
sedation or by a combination of neuraxial blockade and general
anesthesia depending on the surgical procedure and the
preferences of the subject and clinicians. All subjects had an
epidural catheter inserted in the operating room prior to the start
of surgery. The catheters were sited between the T4 and L5
vertebral levels, depending on the dermatomal levels that would be
affected by the surgery; thus, catheters were sited in the lumbar
region for lower limb procedures and in the thoracic region for all
other surgical procedures. Whenever possible, the catheter was
inserted at the vertebral interspace corresponding to the midpoint
of the dermatomal range affected by the surgery. Proper
placement of the epidural catheter was ascertained using a 3-mL
test dose of lidocaine 1% to 2% with epinephrine 1:200000.
Intraoperative neuraxial blockade was achieved using long-acting
local anesthetic (bupivacaine or ropivacaine).
Postoperative epidural analgesia was started upon emergence
from general anesthesia or upon the return of sensation after
neuraxial blockade. A combination of a long-acting local
anesthetic (bupivacaine or ropivacaine) and an opioid (fentanyl,
morphine, or hydromorphone) was used for the epidural infusion
although the combinations varied between centres.
IV group
IntheIVgroup,anesthesiawasachievedusingabalancedgeneral
anesthetic. Postoperative analgesia was initiated upon emergence
from general anesthesia and maintained using IV opioids (fentanyl,
meperidine,morphine,orhydromorphone)administeredaspatient-
controlledanalgesia(PCA)and/orcontinuousinfusiondependingon
the postoperative status of the subject.
Clinical management
The management of anesthesia and postoperative analgesia was
left to the attending anesthesiologists in the operating room and on
the acute pain service. Postoperatively, the goal was to achieve a
state of no or minimal pain (0 to 3 out of 10 on a numeric rating
scale) in the subjects with minimal side effects. Acetaminophen
and non-steroidal anti-inflammatory agents were permitted as co-
analgesics. Epidural and i.v. opioid analgesia were maintained
until the subjects were able to tolerate oral intake and analgesia
was easily achieved with oral analgesics. All other clinical decisions
related to subjects were made by the subjects’ surgical team.
Blinding
Investigators, who were not involved in the care of the subjects,
obtained the bedside data (e.g., clinical signs from the respiratory
examination). In order to blind the investigators, subjects in the IV
group had an epidural catheter (‘‘sham epidural’’) taped to the
surface of their backs prior to induction of anesthesia. The
epidural and intravenous tubings and the analgesic delivery system
were covered during the bedside examinations. An unblinded
Table 1. Inclusion criteria for the PeriOperative Epidural Trial
Pilot Study.
Any patient undergoing non-cardiothoracic surgery and
1. is $45 years old;
2. has an expected length of stay $48 h;
3. is undergoing a procedure amenable to postoperative epidural analgesia;
AND
4. fulfills any of the following SIX criteria
i. history of coronary artery disease;
ii. history of peripheral vascular disease;
iii. history of atherothrombotic stroke;
iv. hospitalization for congestive heart failure within three years of
randomization;
v. undergoing major vascular surgery; OR
vi. has at least THREE of the following factors
a. any history of congestive heart failure,
b. diabetes currently requiring oral hypoglycemic or insulin therapy,
c. history of transient ischemic attack,
d. history of chronic obstructive pulmonary disease,
e. preoperative serum creatinine .175 mmol/L,
f. age .70 years,
g. anticipated duration of anesthesia $3h ,
h. intraperitoneal or intrathoracic surgery,
i. surgery that must be undertaken within 24 h of acute presentation to
hospital
doi:10.1371/journal.pone.0004644.t001
Table 2. Exclusion criteria for the PeriOperative Epidural Trial
Pilot Study.
1. contraindication to epidural analgesia
i. stable platelet count ,50,000 mm
23 or a falling platelet count
,100,000 mm
23;
ii. abnormal INR or aPTT;
iii. ongoing use or planned peri-operative use of anticoagulants;
iv. systemic infection with elevated white blood cell count and temperature
.37.5 degrees Celsius;
v. local infection at proposed site for epidural insertion;
vi. severe cardiac valvular abnormalities that do not tolerate afterload
reduction;
vii. vertebral abnormalities that prevent proper placement of an epidural
catheter or spread of epidural drugs;
2. prior adverse reaction to local anesthetics or narcotics;
3. previous coronary artery bypass graft surgery with complete
revascularization in the preceding five years AND no evidence of cardiac
ischemia since the procedure;
4. pneumonia within two weeks of surgery;
5. currently intubated or mechanically ventilated; OR
6. concomitant life-threatening disease likely to limit life expectancy to ,30
days.
doi:10.1371/journal.pone.0004644.t002
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record and chart and entered all of the data to avoid unblinding
the investigator. An independent, blinded committee adjudicated
any potential clinical events. The database staff and the data
analysts were not blinded to the allocation.
Outcomes
All outcome measures were defined a priori. Our primary
outcome measures for this pilot study were the recruitment rate,
the percent of eligible patients recruited, the crossover rate, and
the percent of successful follow-up at the participating centres. The
centre’s recruitment rate was defined as the number of eligible
patients who participated at the centre over the duration of the
centre’s recruitment period and was expressed as subjects per
week. The study recruitment rate was defined as the mean of all
centres’ recruitment rates and the standard error of the mean. The
percent of all eligible patients who participated was also calculated.
We expressed follow-up as the percent of randomized subjects who
were successfully followed for the 30-day study period. Similarly,
we expressed crossover as the percent of subjects, receiving the
allocated intervention, who switched to the alternate intervention.
The percent crossover was calculated separately for each group.
We considered recruitment feasible for a large multicentre RCT
if we were able to recruit one subject per centre per week (i.e., 200
subjects from four centres over 50 weeks). We considered the pilot
study to be successful, and a large multicentre RCT to be feasible,
if we were able to recruit at least 70% of all eligible patients, no
more than 5% of all recruited subjects crossed over from one
modality to the other, and we achieved complete follow-up in at
least 95% of all recruited subjects.
The secondary outcome measures were the clinical outcome
measures that would be used if a large multicentre RCT was
feasible. The detailed definitions for these outcomes are summa-
rized in Tables 3 and 4. The primary clinical outcome, which
would be used in a full-scale RCT, was a combined 30-day
outcome of all-cause mortality, nonfatal myocardial infarction,
cardiac arrest, postoperative pneumonia, and respiratory failure.
Other secondary outcomes included thromboembolic events (deep
vein thrombosis, pulmonary embolism, transient ischemic attack,
stroke) and congestive heart failure during the first 30 postoper-
ative days, and clinically significant bradycardia and clinically
significant hypotension during the period in which postoperative
epidural or IV opioid analgesia was used.
Data collection
We collected demographic data when informed consent was
obtained. The subject’s physical status and levels of cardiovascular
and respiratory risk were described using the American Society of
Anesthesiologists physical status classification [23], the Revised
Cardiac Risk Index [4,24], and the Postoperative Pneumonia Risk
Index [3] respectively. Details on the anesthetic and postoperative
analgesic were collected immediately after surgery and then daily
while the subjects were receiving epidural or IV opioid analgesia.
Postoperative pain intensity, at rest (static pain) and with
movement (dynamic pain), were measured using a 0 to 10
numeric rating scale (NRS; 0=no pain, 10=worst possible pain)
every four hours after surgery while the subjects were receiving
epidural or IV narcotic analgesia.
For the clinical outcomes, we recorded an electrocardiogram
(ECG) six to 12 hours postoperatively and on the first, second, and
30
th day after surgery. We obtained troponin I levels 6 to 12 hours
postoperatively and on the first, second, and third day after
surgery. If there was clinical suspicion of pneumonia (i.e., new
cough, sputum, dyspnea, fever, altered mental status, or
abnormalities of the white blood cell count or arterial blood
gas), we obtained a chest radiograph and a blinded investigator
performed a pulmonary examination. Additional tests were
ordered at the discretion of the subjects’ clinicians. The subjects’
Table 3. Definition of primary clinical study outcomes to be used if a large multicentre trial is conducted.
Primary Clinical Outcome – Combined 30-day outcome of:
Death Any death regardless of cause
Nonfatal myocardial infarction A typical rise of troponin OR a typical fall of an elevated troponin OR a rapid rise and fall of CK-MB and one of the
following:
1) characteristic ischemic symptoms;
2) development of pathological Q waves on electrocardiogram;
3) electrocardiographic changes indicative of ischemia;
4) coronary artery intervention; OR
5) new or presumed new cardiac wall motion abnormality on echocardiographic or radionuclide imaging
OR pathological findings of acute myocardial infarction
Cardiac arrest Any successful resuscitation from a documented or presumed ventricular fibrillation OR sustained ventricular
tachycardia OR asystole
Clinically significant postoperative pneumonia Any condition with documented hypoxemia (PaO2/FiO2 ratio #250) or fever (temperature .37.5 degrees Celsius)
that meets either of the following criteria:
1) rales or dullness to percussion on chest examination AND any of a) new onset of purulent sputum or change
in sputum character, OR b) organism isolated from blood culture, OR c) pathogen isolated from transtracheal
aspirate, bronchial brushing, or biopsy; OR
2) new or progressive infiltrate, consolidation, cavitation, or pleural effusion on chest radiograph AND any of a)
criteria a, b, or c, as above OR b) isolation of virus or detection of viral antigen in respiratory secretions, OR c)
diagnostic antibody titers, OR histopathologic evidence of pneumonia
Respiratory failure Any condition requiring intubation of the trachea and mechanical ventilation AFTER completion of surgery,
emergence from anesthesia, successful extubation (if intubated during surgery), and spontaneous ventilation for
$1 h after surgery
doi:10.1371/journal.pone.0004644.t003
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Thirty days after surgery, a research coordinator interviewed
subjects by telephone. If subjects indicated they had experienced
an outcome within the first 30 days after surgery, their physicians
were contacted to acquire the appropriate documentation.
Data management
For data entry, we used secure, web-based, electronic case
report forms developed by the central coordinating office. Data
were entered online daily during each subject’s hospital stay and
were stored in a secure SQL Server database. Source documents
were stored locally in locked premises at each centre. All computer
systems used in the study were located in locked, high-security
areas of the Centre for Clinical Epidemiology and Evaluation at
the Vancouver Coastal Health Research Institute.
Statistical methods
Preliminary sample size calculations prior to this pilot study
suggested the need for a sample size as low as 932 subjects (25%
incidence rate, 30% relative risk reduction, 5% type I error rate,
and 80% power) to as high as 8604 subjects (10% incidence rate,
20% relative risk reduction, 5% type I error rate, and 90% power)
for a full-scale multicentre RCT. The need for a more precise
estimate of the incidence rate was one reason to conduct a pilot
study. For this pilot study, we based our sample size on the
number of participating centres and the minimum weekly
recruitment per centre that we would tolerate if the true incidence
rate was 20% (yielding a sample size of 1250 for a 25% relative risk
reduction, 5% type I error rate, and 90% power). Our experience
with the PeriOperative ISchemic Evaluation (POISE) Trial [13]
indicated that 25 centres would likely participate in Canada. To
ensure that the results of a large RCT would be clinically relevant
(i.e., not outdated with respect to clinical management) at least one
subject should be recruited weekly from each centre (1250
subjects/25 sites/50 subjects per site per year=2 years). Thus,
our target sample size was 200 subjects (one subject per week per
centre for 50 weeks for 4 centres).
Continuous data were summarized with means and standard
deviations for normally distributed data and with medians and
interquartile ranges for skewed data. Discrete data were reported
as absolute numbers and percentages. We anticipated that the
number of pain score measurements over each day could vary
between subjects; therefore, pain score data for each group and
time interval were summarized using means and standard
deviations weighted by the number of measurements per subject
[25]. We reported the number of events in each group but we did
not make any comparisons using inferential statistics as this pilot
study did not have the power to detect meaningful differences. For
the primary clinical outcome that would be used in a full-scale
RCT, the event rate and its 95% confidence interval (CI) were
calculated for each group. Data from all subjects were reported as
randomized in keeping with the intention-to-treat principle.
Results
Figure 1 describes the flow of subjects in the POET Pilot Study.
From May 25, 2005 to August 31, 2006, 929 patients were
screened in the preoperative assessment clinics at the Hamilton
Health Sciences (McMaster Site), Ottawa Hospital (Civic
Campus), Toronto General Hospital, and Vancouver General
Hospital. The study recruitment rate was 0.560.3 subjects per
week per centre; the recruitment rate varied between centres
(Table 5). Four hundred and ninety-four patients were eligible;
112 (22.7%) consented to participate in this study. Of the 112
consenting subjects, 101 were successfully allocated – 50 to the
epidural group and 51 to the IV group. Eleven subjects could not
be randomized for various reasons (Figure 1). Thirteen of the 49
subjects (26.5%) in the epidural group had crossed over to i.v.
opioid analgesia due to refusal of the subject to receive an epidural
catheter (n=1), refusal of the clinicians (n=3), failure to insert the
epidural catheter (n=2), inadequate analgesia (n=3), excessive
motor blockade (n=1), development of postoperative complica-
tions that required treatment with anticoagulants (n=2), or
unstated reasons (n=1). Five subjects (9.8%) in the IV group
crossed over to epidural analgesia due to refusal of the clinicians
(n=3) or unstated reasons (n=3); none were due to inadequate
analgesia or complications related to IV opioids. Another three
subjects never received the allocated intervention due to
withdrawal of consent (n=2) or cancellation of surgery (n=1).
By the end of the first 24 hours after surgery, 35/50 (70.0%)
and 43/51 (84.3%) of the subjects in the epidural and IV
groups respectively were receiving their allocated interventions.
Table 4. Definition of secondary clinical study outcomes to be used if a large multicentre trial is conducted.
Deep vein thrombosis Any clinical suspicion of deep vein thrombosis (lower limb pain OR tenderness OR swelling OR edema) AND objective
diagnostic confirmation (positive lower limb venogram with constant intraluminal filling defect seen on $2 views OR
compression ultrasound demonstrating a noncompressible vein segment)
Pulmonary embolus Any clinical suspicion of pulmonary embolus (chest pain OR shortness of breath) AND objective diagnostic confirmation
1) definite pulmonary embolus=a pulmonary angiogram with a constant intraluminal filling defect OR a spiral computed
tomogram with an unenhanced filling defect seen in a central pulmonary artery OR a high-probability ventilation-
perfusion scan OR an intermediate ventilation-perfusion scan with venographic evidence of deep vein thrombosis OR
autopsy evidence of pulmonary embolus
2) probable pulmonary embolus=an intermediate ventilation-perfusion scan with clinical signs
Transient ischemic attack Any new focal neurological deficit of vascular origin that lasts ,24 h with no permanent neurological sequelae
Stroke Any new focal neurological deficit of vascular origin with signs and symptoms lasting $24 h
Congestive heart failure Any condition with both clinical (elevated jugular venous pressure OR respiratory rales OR crepitations OR presence of S3)
AND radiological (vascular redistribution OR interstitial pulmonary edema OR frank pulmonary edema) evidence consistent
with congestive heart failure
Clinically important bradycardia Heart rate ,60 bpm requiring temporary pacing, a sympathomimetic agent, or atropine
Clinically important hypotension Systolic blood pressure that is at least 20% lower than the preoperative systolic blood pressure AND requires fluid
resuscitation, a vasopressor, or an inotropic agent
doi:10.1371/journal.pone.0004644.t004
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followed for the entire study period.
Tables 6 and 7 report the characteristics of the subjects, surgery,
and anesthetic in each group.
Figure 2 and 3 summarizes the duration of anesthesia,
postoperative analgesia, and length of hospital stay in each group.
The central tendency and dispersion of the data were similar in
both groups for all three time periods. Subjects in the epidural
Figure 1. Flow of subjects through the PeriOperative Epidural Trial Pilot Study.
doi:10.1371/journal.pone.0004644.g001
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Centre Eligible Patients, n Consented Subjects, n( % ) * Weeks of Recruitment Recruitment Rate, subject/week (95% CI)
Hospital A 117 35 (30) 50 0.7 (0.6–0.8)
Hospital B 31 10 (32) 26 0.4 (0.2–0.6)
Hospital C 206 57 (28) 64 0.9 (0.8–1.0)
Hospital D 140 10 (7) 56 0.2 (0.1–0.3)
Abbreviation: 95% CI, 95% confidence interval.
*Percentage denotes the percentage of eligible patients who consented to participate.
doi:10.1371/journal.pone.0004644.t005
Table 6. Characteristics of subjects recruited in the
PeriOperative Epidural Trial Pilot Study.
Descriptor
Epidural
Group (n=49)
IV Group
(n=49)
Mean age6SD, year 70.967.6 70.368.6
Sex, n( % )
Female 12 (24.5) 15 (30.6)
Male 38 (77.6) 36 (73.5)
Comorbid conditions, n( % )
Coronary artery disease 14 (28.6) 12 (24.5)
Peripheral vascular disease 13 (26.5) 11 (22.4)
Stroke/transient ischemic attack 1 (2.0) 4 (8.2)
Congestive heart failure 2 (4.1) 0 (0.0)
Hypertension 34 (69.4) 31 (63.3)
Diabetes mellitus 11 (22.4) 14 (28.6)
Chronic renal dysfunction 2 (4.1) 0 (0.0)
Smoker
Former 18 (36.7) 24 (49.0)
Current 11 (22.4) 7 (14.3)
Chronic obstructive pulmonary disease 4 (8.2) 7 (14.3)
Medication history, n( % )
Aspirin 16 (32.6) 21 (42.8)
Clopidogrel/ticlopidine 2 (4.1) 2 (4.1)
Warfarin 1 (2.0) 2 (4.1)
Heparins 1 (2.0) 2 (4.1)
Statins 26 (53.1) 22 (44.9)
Nitrates 2 (4.1) 4 (8.2)
Diuretics 15 (30.6) 15 (30.6)
ACE inhibitors/angiotensin II receptor
blockers
23 (46.9) 19 (38.8)
Beta-adrenergic blockers 16 (32.6) 21 (42.8)
Calcium channel blockers 8 (16.3) 17 (34.7)
Digoxin 2 (4.1) 3 (6.1)
Amiodarone 1 (2.0) 2 (4.1)
Beta-agonist bronchodilators 1 (2.0) 1 (2.0)
Inhaled steroids 3 (6.1) 1 (2.0)
Abbreviation: ACE, angiotensin converting enzyme; SD, standard deviation.
doi:10.1371/journal.pone.0004644.t006
Table 7. Level of risk and type of surgery and anesthesia by
group.
Descriptor
Epidural Group
(n=49)
IV Group
(n=49)
Risk scores
ASA physical status, n( % )
Class I 0 (0.0) 0 (0.0)
Class II 16 (32.6) 13 (26.5)
Class III 28 (57.1) 30 (61.2)
Class IV 4 (8.2) 5 (10.2)
RCRI score, n( % )
0 risk factor 3 (6.1) 3 (6.1)
1 risk factor 23 (46.9) 25 (51.0)
2 risk factors 20 (40.8) 15 (30.6)
$3 risk factors 3 (6.1) 6 (12.2)
PPRI score, n( % )
Class 1 (0–15 points) 5 (10.2) 4 (8.2)
Class 2 (16–25 points) 19 (38.8) 18 (36.7)
Class 3 (26–40 points) 22 (44.9) 25 (51.0)
Class 4 (41–55 points) 2 (4.1) 1 (2.0)
Class 5 (.55 points) 0 (0.0) 0 (0.0)
Type of surgery, n( % )
Intra-abdominal 28 (57.1) 26 (53.1)
Gynecological 3 (6.1) 6 (12.2)
Urological 6 (12.2) 7 (14.3)
Vascular 13 (26.5) 11 (22.4)
Type of anesthesia
General anesthesia only 6 (12.2) 44 (89.8)
GA+neuraxial blockade
GA+thoracic epidural 32 (65.3) 3 (6.1)
GA+lumbar epidural 5 (10.2) 1 (2.0)
GA+spinal 1 (2.0) 0 (0.0)
GA+combined spinal-epidural 0 (0.0) 0 (0.0)
Neuraxial anesthesia only
Thoracic epidural 1 (2.0) 1 (2.0)
Lumbar epidural 4 (8.2) 0 (0.0)
Spinal 0 (0.0) 0 (0.0)
Combined spinal-epidural 0 (0.0) 0 (0.0)
Abbreviation: ASA, American Society of Anesthesiologists; GA, general
anesthesia; PPRI, Postoperative Pneumonia Risk Index; RCRI, Revised Cardiac
Risk Index.
doi:10.1371/journal.pone.0004644.t007
The POET Pilot Study
PLoS ONE | www.plosone.org 7 February 2009 | Volume 4 | Issue 2 | e4644group received epidural or IV opioid analgesia for a median of 3.0
days (IQR 1.9–4.0 days). Those in the IV group received IV
opioid or epidural analgesia for a median of 2.7 days (IQR 1.8–4.3
days). When the data were summarized on the basis of the actual
analgesic received, subjects received epidural and IV opioid
analgesia for a median of 3.7 days (IQR 2.4–4.5 days) and 2.4 days
(IQR 1.7–3.7 days) respectively. The median length of hospital
stay was 7 days in both groups and all reported clinical events were
observed during that period.
Table 8 reports the clinical events observed in this study. The
event rate for the combined outcome of all-cause mortality, non-
fatal myocardial infarction, non-fatal cardiac arrest, postopera-
tive pneumonia, and respiratory failure was 16.3% (8/49; 95%
CI 8.5%–29.0%) in the epidural group and 14.2% (7/49; 95%
CI 7.1%–27.0%) in the IV group. One other subject in the IV
group died after the study period on the sixtieth day after
surgery. Thromboembolic events (two deep vein thromboses,
one pulmonary embolus, and one stroke) were observed in four
subjects in the IV group. Two subjects in the epidural group had
clinically significant bradycardia; three subjects (two in the
epidural group, one in the IV group) had clinically significant
hypotension; and one subject experienced a sudden postopera-
tive loss of consciousness, which was attributed to the epidural
analgesia. This subject did not suffer any sequelae from the
serious adverse event. We have not made any between-group
comparisons of the clinical events as this study was not powered
for such comparisons and conclusions from such comparisons
would be misleading.
Subjects in both groups received adequate analgesia to relieve
static pain. Static pain scores over the duration of the intervention,
expressed as weighted mean6standard deviation, were 1.561.2 in
the epidural group and 2.561.3 in the IV group. Figure 4 depicts
the pain scores by postoperative day for each group. Too few
Figure 2. Box plots of duration of intraoperative anesthesia in
hours and postoperative analgesia in days. Blue denotes the
epidural group; green denotes the IV group. Circles indicate individual
data points, the horizontal bars denote the median durations, and the
boxes denote the interquartile range.
doi:10.1371/journal.pone.0004644.g002
Figure 3. Box plot of duration of hospital stay in days. Blue
denotes the epidural group; green denotes the IV group. Circles
indicate individual data points, the horizontal bars denote the median
durations, and the boxes denote the interquartile range.
doi:10.1371/journal.pone.0004644.g003
Table 8. Number of events observed by clinical outcome and
group.*
30-day Clinical Outcomes
Epidural Group
(n=49) IV Group (n=49)
Primary outcome, n (%; 95% CI) 8 (16.3; 8.5–29.0) 7 (14.2; 7.1–27.0)
Outcomes comprising
combined primary outcome,
n( % )
Death 0 (0.0) 1 (2.0){
Nonfatal myocardial infarction 4 (8.2) 2 (4.1)
Cardiac arrest 0 (0.0) 0 (0.0)
Postoperative pneumonia
Definite 1 (2.0) 1 (2.0)
Probable 3 (6.1) 1 (2.0)
Respiratory failure 0 (0.0) 2 (4.1)
Secondary outcomes, n( % )
Deep vein thrombosis 0 (0.0) 2 (4.1)
Pulmonary embolus
Definite 0 (0.0) 1 (2.0)
Probable 0 (0.0) 0 (0.0)
Transient ischemic attack 0 (0.0) 0 (0.0)
Stroke 0 (0.0) 1 (2.0)
Congestive heart failure 0 (0.0) 0 (0.0)
Clinically important bradycardia 2 (4.1) 0 (0.0)
Clinically important hypotension 2 (4.1) 1 (2.0)
Serious adverse event
Loss of consciousness 1 (2.0) 0 (0.0)
Abbreviation: 95% CI, 95% confidence interval.
*Note that zero events in a sample of 49 subjects still yields an upper 95%
confidence limit of 0.073 for the 30-day incidence rate.
{In addition to the subject who died within the 30-day study period, another
subject died 60 days after surgery.
doi:10.1371/journal.pone.0004644.t008
The POET Pilot Study
PLoS ONE | www.plosone.org 8 February 2009 | Volume 4 | Issue 2 | e4644dynamic pain scores were recorded in subjects (epidural group,
median 6 measurements; IV group, median 4 measurements) to
permit meaningful summary or interpretation.
Discussion
Over a 66-week period, the study recruitment rate was 0.560.3
subjects per week per centre, which was approximately half of the
target recruitment rate of 1 subject per week per centre. Research
staff from four Canadian tertiary-care teaching hospitals screened
929 patients and recruited 112 (22.7%) of 494 patients who were
eligible for this pilot study. A total of 18 subjects (13 from the
epidural group; 5 from the IV group) crossed over to the
alternative group regardless of reason. The crossover rate in the
epidural group due to failed or inadequate analgesia or
complications from epidural analgesia was 14.3% (7/49), which
exceeded the target crossover rate of no more than 5%. There
were no crossovers in the IV group related to inadequate analgesia
or complications from IV opioids. We achieved our target follow-
up rate and successfully followed 97.0% (98/101) of the
randomized subjects.
Our target recruitment rate was ambitious. In trials, published
in this millennium, that compared epidural analgesia to IV
analgesia, recruitment rates ranged from 0.5 to 3.5 subjects per
month per centre (Table 9) [21,26–30]. Although the recruitment
rates were within the range reported in other studies, even in the
centre with the lowest recruitment rate in our study, the percent of
eligible patients recruited was low compared to other trials
(Table 9).
Our ability to recruit subjects was limited by several factors.
First, nearly half (222/494; 44.9%) of all eligible subjects declined
to participate (Figure 1). Ninety-seven (19.6%) of the eligible
patients had decided on either epidural analgesia or intravenous
PCA already by the time they were approached by the study
coordinators. Another 125 (25.3%) declined for various reasons, of
which the most common was a lack of interest or aversion,
expressed by the patient or the family members, in being a
research subject. We could not determine whether the comparison
of an invasive intervention (epidural analgesia) to a relatively non-
invasive intervention (IV analgesia) influenced the patients’
decisions. However, our observations are consistent with those of
other investigators, who have found epidural anesthesia to be a
deterrent to participation in clinical research [31,32].
Second, competition between another RCT affected our study’s
recruitment. All four centres were participating in the POISE
Trial [14], a study with similar selection criteria and outcome
measures [34], at the time of this study. We had hypothesized that
concurrent conduct of the two similarly designed studies would
increase efficiency in screening, consent, and follow-up. We
anticipated that most moderate- to high-risk patients would be
eligible for one of the two studies, but not both. As the POISE
Trial had started before the POET Pilot Study, we had agreed a
priori that any patient eligible for both studies would be invited to
participate in the POISE Trial. This situation occurred in 41
(8.2%) of our eligible patients. We estimate that another 12
patients would have enrolled in our study in the absence of the
POISE Trial.
Third, the comfort level of clinicians with leaving the choice of
analgesia to chance may have affected our ability to recruit
subjects at one of the four centres. At each centre, the members
of the departments of anesthesia and surgery had agreed to
participate in this study. The four centres had similar, well-
established epidural and intravenous analgesic policies and active
postoperative pain services, yet anesthesiologists and surgeons
prevented 87 patients (17.6%) from participating (Figure 1).
Seventy-seven (88.5%) of these cases involved vascular patients
Figure 4. Box plots of numeric rating scale scores for static pain by group and postoperative day. The horizontal bars denote the
median pain score, the boxes denote the interquartile range, the lower whiskers denote the lowest value lying within the first quartile subtract 1.5
times the interquartile range, the upper whiskers denote the highest value lying within the third quartile plus 1.5 times the interquartile range, and
dots denote outliers.
doi:10.1371/journal.pone.0004644.g004
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postoperative analgesic modality was epidural analgesia for
supraumbilical procedures and intravenous analgesia for infra-
umbilical procedures. Although clinicians were comfortable
recruiting other types of moderate- to high-risk surgical patients
at that centre, they were reluctant to change their practice
regarding vascular patients.
The reluctance to leave the choice of analgesia to chance was
also seen after consent and allocation (Figure 1). Anesthesiologists
prevented another four subjects from undergoing allocation and
surgeons and anesthesiologists refused to use the allocated
intervention (i.e., protocol violation) in six subjects. In these ten
cases (Hospital A n=2; Hospital C n=6; Hospital D n=2), the
clinicians decided that one of the two analgesic modalities would
be of greater benefit for their particular subject and were unwilling
to accept the alternative. Clinicians cited their own expert
knowledge, concerns of patient safety, fears of inadequate
analgesia (when allocation was to the IV group), or too much
analgesia (when allocation was to the epidural group) as reasons
for preventing allocation or violating the protocol.
Failed or inadequate analgesia or complications from epidural
analgesialedtodiscontinuationofepiduralanalgesiainsevensubjects
in the epidural group (Hospital A n=1;HospitalBn=2;HospitalC
n=3;HospitalDn=1). The number of cases at each centre was too
small to determine whether variations in clinical practice between
centres played any role. The crossover rate from epidural to IV
analgesia in our study (14.3%) was in keeping with rates reported in
recent RCTs, which have ranged from 6.5% to 19.4% with larger
trials reporting lower rates of crossover (Table 9) [21,22,30].
Our original intent was to conduct a national multicentre RCT
over a two-year period in approximately 25 centres. Based on the
results of this pilot study, our original plan is infeasible. Using the
lower 95% confidence limit for the event rate in the IV group
(7.1%), 25% relative risk reduction, 5% type I error, and 80%
power, the sample size would be 6148. Sixty-two centres would
need to recruit 0.5 subjects per week to complete recruitment in
four years. A study of that size and duration would need to be
international and would be very expensive.
We conducted this study in academic centres of two Canadian
provinces only. Preliminary work using the Canadian Institute for
Health Information Discharge Abstract Database indicated a wide
variation in the use of neuraxial blockade between provinces and
between academic and community hospitals in Canada. For
example, the rate of neuraxial blockade for major joint
arthroplasties in Canada during the year 2000 varied from
39.9% (British Columbia) to 65.6% (Alberta) for academic centres
and from 19.2% (Alberta) to 33.0% (Ontario) for community
hospitals [Unpublished work by Peter Choi, P.J. Devereaux,
Gordon Guyatt, and Bruce Weaver]. Thus, our results may not
reflect the research culture or the feasibility of conducting an RCT
comparing epidural analgesia to IV analgesia in centres from other
Canadian provinces or countries or in community hospitals in
British Columbia and Ontario.
In summary, the results of this pilot feasibility RCT suggest that
a large, multicentre RCT is an impractical design for comparing
epidural analgesia with IV analgesia with regards to perioperative
cardiorespiratory outcomes. Our results show patients and
clinicians are reluctant to leave the choice of postoperative
analgesia to chance. Several other barriers make a large RCT
impractical. Recent work suggests changes in perioperative care
over the past few decades are resulting in reductions in
perioperative complications. Po ¨pping and colleagues [34] show
decreases over the past 35 years in the risk of postoperative
pneumonia with systemic analgesia, which has lessened the
potential benefits of epidural analgesia and would necessitate
larger sample sizes to detect clinically relevant and plausible
differences in outcomes between analgesic modalities. The use of
epidural analgesia across diverse surgical populations raises the
issue of generalizability of results versus applicability of results to a
specific population. Whereas the inclusion of many types of
patients will increase the generalizability of the results of an RCT
if a difference is found, clinical heterogeneity will be criticized if an
RCT fails to detect a difference. Clinicians will likely argue that
the wrong population was studied in the latter case; however,
restriction to a specific population can increase the difficulty in
recruitment due to a lower number of eligible patients. Lastly, the
Table 9. Rates of recruitment, crossover, and follow-up reported in recent randomized controlled trials evaluating epidural
analgesia.
Study Recruitment Period
Number of
Subjects
Number of
Centres
Recruitment
Rate Subject/
month/centre
Eligible Patients
Recruited n( % ) Crossover n( % )
Complete
Follow-up
n( % )
Epidural
to IV
IV to
Epidural
Norris 2001 [21] August 1993–July 1997 160 1 3.5 175/247 (70.8) N/R N/R N/R
VACS 2001 [22] N/R 1021 15 N/R 1021/1371 (74.5) 32/489 (6.5) 48/495
(9.7)
973/984
(98.9)
Steinberg 2002 [27] July 1997–August 1998 48 5 0.7 N/R N/R N/R 41/48 (85.4)
Carli 2002 [28] April 1998–April 2000 64 2 1.3 N/R N/R N/R 64/64 (100)
MASTER 2002 [21] July 1995–May 2001 920 25 0.5 N/R 29/447 (6.5) 19/441
(4.3)
N/R
Katz 2003 [29] August 1995–August 2000 212 2 1.8 212/684 (31.0) N/A* N/A* N/R
Zutshi 2005 [30] N/R 59 1 N/R N/R 6/31 (19.4) 0/28 (0.0) 35/59 (59.3)
POET Pilot 2008 May 2005–August 2006 112 4 2.0 112/494 (22.7) 7/49 (14.3) 0/49 (0.0) 98/101 (97.0)
Abbreviations: N/A, not applicable; N/R, not reported.
*All patients received IV patient-controlled analgesia after surgery.
doi:10.1371/journal.pone.0004644.t009
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observational studies.
Considering the challenges of using RCT methods to study the
effect of epidural blockade on clinical outcomes, observational
methods, such as a prospective cohort study, may be more feasible
though subject to more biases. Furthermore, research using
qualitative methods, is needed to explore the barriers to the
conduct of randomized controlled trials comparing neuraxial
blockade to non-invasive interventions [35].
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